Annovis Bio completes enrollment of 850 patients in pivotal Phase 3 AD trial of buntanetap

Annovis Bio, Inc.

Enrolled 850 pTau217-confirmed early AD patients across 83 US sites, exceeding original projections.
Symptomatic top-line data expected Q1 2027; disease-modifying data expected Q1 2028.
Company plans two NDA submissions to FDA after each respective data readout.
Trial is randomized, placebo-controlled, double-blind with daily oral buntanetap 30mg.
Last patient completes 6-month treatment in January 2027; study on track.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.